Archivos suplementarios
Palabras clave
inmunodeficiencia secundaria
inmunocompetentes
tratamientos inmunomoduladores
Cómo citar
Plaudit
Resumen
Las inmunodeficiencias secundarias aparecen en individuos previamente inmunocompetentes. La falta de respuesta primaria o secundaria a un antígeno extraño, en el caso de infecciones, es un dato centinela en el diagnóstico de inmunodeficiencia (puede ser primaria o secundaria); en el caso de un antígeno propio podría generar cáncer. Éste ha mostrado un aumento en la prevalencia e incidencia en forma global. La mayor parte de los tratamientos médicos actuales en cáncer se enfocan, fundamentalmente, a acciones inmunomoduladoras (inmunosupresióninmunoestimulación o ambos). El conocimiento de los conceptos clave, desde la perspectiva de la inmunidad innata y adquirida, conduce al desarrollo de cáncer, involucrándose a la vigilancia inmunológica y los mecanismos de escape de ésta, que contribuyen a comprender mejor el origen, comportamiento y tratamiento de las neoplasias. Los tratamientos pueden originar alteraciones inmunológicas como: alergia, anafilaxia, falta de respuesta por inmunogenicidad, campos de atención del especialista en Alergia e Inmunología clínica.
Referencias
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-674.
Whiteside TH, Robinson BWS, June GH, Lotze MT. Principles of tumour immunology. In: Robert E Rich Ed. Clinical Immunology. 4a ed. 2013;925-934
Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science 2011;331:1565-1570.
Finn OJ. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Ann Oncol 2012; 23 (Sup. 8): viii6-viii9, doi:10.1093/annonc/mds256.
Mnich SJ, Veenhuizen AW, Monahan JB, Sheehan KC, Lynch KR, et al. Characterization of a monoclonal antibody that neutralizes the activity of prostaglandin E2. J Immunol 1995;155: 4437-4444.
Stockert E, Jäger E, Chem Y-T, Scanlan MJ, Gout I, Karbach J, et al. A Survey of the Humoral Immune Response of Cancer Patients to a Panel of Human Tumor Antigens. J Exp Med 1998; 187 (8): 1349-1354.
Salazar FO. El sistema inmunológico, herramienta estratégica en la batalla contra el cáncer. Rev Chil Ped 2000; 71; 4 http://dx.doi.org/10.4067/S0370-41062000000400003
Vargas-Camaño ME. Inmunodeficiencias secundarias de tipo metabólico. 1a. Parte. Galenus; 2015;2(6): 6-10.
Galdieroa MR, Bonavitas E, Barajonc I, Garlandaa C, Mantovania A, Jaillona S. Tumor associated macrophages and neutrophils in cancer. Inmunobiol 2013; 218(11:1402-1410 doi:10.1016/j.imbio.2013.06.00
Soulo JC, Via L, Brú A. Polymorphonuclear neutrophils and cancer: Intense and sustained neutrophilia as a treatment against solid tumors. Med Res Rev 2011; 31 (3): 311-363. DOI:10.1002/med.20185
Mantovani A. Macrophages, Neutrophils, and Cancer: A Double Edged Sword. New Journal of Science Vol. 2014, Article ID 271940, 14 pages http://dx.doi. org/10.1155/2014/271940
Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, et al. IFN-γ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001; 410, 1107-1111 doi:10.1038/35074122
Al Omar SY. Marshall E, Middleton D, Christmas SE. Increased numbers but functional defects of CD56+CD3+ cells in lung cancer. International Immunology, Vol. 24(7): 409-415 doi:10.1093/intimm/dxr122
Magné N, Toillon RA, Bottero V, Didelot C, Van Houtte P, Gérard JP, Peyron JF. NF-κB modulation and ionizing radiation: mechanisms and future directions for cancer treatment. Cancer Let 2006;231:158-168.
Camellet P. VEGF as a key mediator of angiogenesis in cancer. Oncology 2005; 69 (Sup 3): 4-10.
Carbone DP. Immune Dysfunction in Cancer Patients Cancer Network. January 2002: 1-10.
Mandell GL, Fisher RI, Bostick F, Young RC. Ovarian cancer: A solid tumor with evidence of normal cellular immune function but abnormal B cell function. Am J Med 1979; 66; 621-62.
Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P. Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nature Medicine 2004;10, 942-949. doi:10.1038/ nm1093
Mussai F, Egan S, Hunter S, Webber H, Fisher J, Wheat R, McConville C, et al. Neuroblastoma arginase activity creates an immunosuppressive microenvironment that impairs autologous and engineered immunity. Can Res Published Online First June 8, 2015; DOI: 10.1158/0008- 5472.CAN-14-3443
Pollack IF, Okada H, Chambers WH. Exploitation of immune mechanisms in the treatment of central nervous system cancer. SemPediatric Neurol 2000; 7: 131-143
Tougeron D, Fauquembergue E, Latouche JB. Inmune response and colorrectal cáncer. (Artículo en francés) Bull Cáncer. 2013 Mar; 100(3):283-94. doi: 10.1684/bdc.2013.1716.
Steele G, Lahey S, Rodrick M, Ross D, Deasy J, Zamcheck N, Osteen R, Wilson R. Circulating immune complexes in patients with colorectal cancer. Am J Surg 1983; 145: 549-553.
Van Cutsem E, Aren J .The causes and consequences of cancer-associated malnutrition. Eur J Oncol Nurs 2005:(9): 51-S63.
Argilés JM. Cancer-associated malnutrition. Eur J Oncol Nurs 2005;9(S2): S39-S50.
Gur C. Ibrahim Y, Isaacson B, Yamin R, AbedJ,GamlielM. Enk J, et al. Binding of the Fap2 Protein of Fusobacterium nucleatum to Human Inhibitory Receptor TIGIT Protects Tumors from Immune Cell Attack. Immunity. 2015; 42 (2): 344-355.
Jungbluth AA, Busam KJ, Kolb D, Iversen K, Coplan K, et al. Expression of MAGE-antigens in normal tissues and cancer. Int J Cancer. 2000 15; 85(4):460-5.
Türeci O, Sahin U, Schobert I, Koslowski M, Schmitt H, Schild H-J, et al. The SSX-2 gene, which is involved in the t (X; 18) translocation of synovial sarcomas, codes for the human tumor antigen HOM-MEL-40. Can Res.1996; 56:4766-4772.
Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, et al. Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NYESO- 1. Clin Oncol 2011 Mar 1; 29(7): 917-924, doi:10.1200/ JCO.2010.32.2537.
Pollack SM, Jungbluth AA, Hoch BL, Farrar EA, Bleakley M, et al. NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma. Cancer. 2012 Sep 15; 118(18):4564-70. doi: 10.1002/ cncr.27446.
Yu Q, Sicinska E, Geng Y, Ahnström M, Zagozdzon A, Kong Y, Gardner H, et.al. Requirement for CDK4 kinase function in breast cancer. Cancer Cell. 2006 Jan;9(1):23-32.
Liu F, Korc M. Cdk4/6 Inhibition Induces Epithelial- Mesenchymal Transition and Enhances Invasiveness in Pancreatic Cancer Cells. Mol Cáncer Ther. 2012 11; 2138.10.1158/1535-7163.MCT-12-0562.
Goldstein AM, Chidambaram A, Halpern A, Holly EA, Guerry IV D, et.al. Rarity of CDK4 germline mutations in familial melanoma.Melanoma Res. 2002 Feb; 12(1):51-5.
Merimsky O, Shoenfeld Y, Baharav E, Zigelman R, Fishman P. Reactivity to tyrosinase: expression in cancer (melanoma) and autoimmunity (vitiligo). Hum Antibodies Hybridomas. 1996; 7(4):151-6.
Sellapan S, Grijalva R, Zhou X. Yam W, Bar Eli M, Mills GB, Yu D. Lineage Infidelity of MDA-MB-435 Cells. Expression of Melanocyte Proteins in a Breast Cancer Cell Line. Cancer Res May 15, 2004 64; 3479.doi: 10.1158/0008-5472. CAN-3299-2.
Berset M, Cerottini JP, Guggisberg D, Romero P, et al. Expression of Melan-A/MART-1 antigen as a prognostic factor in primary cutaneous melanoma. Int J Cáncer 2001;20 (95): 73-7.
Tazzari M, Palassini E, Vergani B, Villa A, Rini F, Negri T, et al. Melan-A/MART-1 immunity in a EWS-ATF1 translocated clear cell sarcoma patient treated with sunitinib: a case report. BMC Cancer 2015, 15:58 doi:10.1186/s12885- 015-1044-0
Hoffman M, Stoss O, Shi D, Büttner R, Van de Vijver M, Kim W, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathol 2008; 52 (7) 797-895. DOI: 10.1111/j.1365- 2559.2008.03029.x.
Hirsch FR, Franklin WA, Veve R, Varella-García M, Bunn Jr PA.HER2/neu expression in malignant lung tumors. Sem Oncol 2002; 29 (1, S1): 51-58 doi:10.1053/s0nc.2002.31523
Leppilampi M, Koistinen P, Savolainen E-R, Hannuksela J, Parkkila AK, et al. The Expression of Carbonic Anhydrase II in Hematological Malignancies. Clin Cancer Res 2002: 8; 2240-2245.
Atkins M, Regan M, McDermott D, Mier J, Stanbrigde E, Youmans A, Febbo P, et al. Carbonic Anhydrase IX Expression Predicts Outcome of Interleukin 2 Therapy for Renal Cancer. Clin Cancer Res 2005; 11; 3714-3721, doi: 10.1158/1078-0432.CCR-04-2019.
Olive PL, Aquino-Parsons C, MacPhail SH, Liao S-Y, Raleigh JA, et al. Carbonic Anhydrase 9 as an Endogenous Marker for Hypoxic Cells in Cervical Cancer. Cancer Res 2001; 61: 8924-8929.
Türeci Ö, Sahin U, Vollmar E, Siemer S, Göttert S, Seitz G, Parkkilal A-K, et al. Human carbonic anhydrase XII: cDNA cloning, expression, and chromosomal localization of a carbonic anhydrase gene that is overexpressed in some renal cell cancers. PNAS 1998; 95 (13) 7608-7613.
Kim S, Kim N, Dong B, Boren D, Lee SA, Das Gupta J, Gaughan C, et al. Integration Site Preference of Xenotropic Murine LeukemiaVirus-Related Virus, a New Human Retrovirus Associated with Prostate Cancer. J. Virol 2008; 82 (20): 9964-9977.
Bosch FX, Manos MM, Muñoz N, Sherman M, Jansen AM, Peto J, et al. Prevalence of Human Papillomavirus in Cervical Cancer: a Worldwide Perspective. International Biological Study on Cervical Cancer (IBSCC) Study GroupJ Natl Cancer Inst 1995; 87 (11): 796-802 doi: 10.1093/jncj/87.11.796.
Centers for Disease Control and Prevention (CDC).HPVAssociated Penile Cancer Rates by Race and Ethnicity. Human papillomavirus-associated cancers-United States, 2004-2008 MMWR 2012; 61(15):258-261.
Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, et al. Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States. J Clin Oncol.2011; 29:4294-4301.
Fáhraeus R, Lu HL, Emberg I, Finke J, Rowe M, Klein G, et al. Expression of Epstein-Barr virus-encoded proteins in nasopharyngeal carcinoma. Int J Cancer 1998; 42 (3): 329-338 DOI 10.1002/ijc.2910420305.
Bollard CM, Gottschalg S, Leen AM, Weiss H, Straathof KC, Carrum G, et al. Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood 2007; 110 (8):2838-2845.
Khan AA1, Khan Z2, Warnakulasuriya S3.Cáncer associated Toll like receptor modulation and insinuation in infection susceptibility: association or coincidence? Ann Oncol. 2016 Feb 9.pii: mdw053. Epub ahead of print.
Mukherjee D, Devi KR, Deka M, Malakar M, et al. Association of toll-like receptor 2 Δ22 and risk for gastric cancer considering main effects and interactions with smoking: a matched case-control study from Mizoram, India. Tumour Biol. 2016 Feb 15. Epub ahead of print.
Hirvonen K, Bäck L, Haglund C, et al. Toll-like receptor 5 and 7 expression in adenoid cystic carcinoma of major salivary glands. Tumour Biol. 2016 Feb 18. Epub ahead of print.
Jha HC, Banerjee S, Robertson E. The Role of gamma herpesviruses in cancer pathogenesis. Pathogens. 2016 Feb 6; 5(1).pii: E18. doi: 10.3390/pathogens5010018.
Baggio L, Laureano ÁM, da Rocha Silla LM, Lee DA. Natural killer cell adoptive immunotherapy: Coming of age. Clin Immunol. 2016 Feb 13. pii: S1521-6616(16)30019-5. doi: 10.1016/j.clim.2016.02.003. Epub ahead of print.
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial 4.0.
Derechos de autor 2016 Revista Alergia México